No safety issues noted
Study ongoing; interim analysis on un-blinded data expected during Q3 2016
Average rate of viral lesions in patients who completed dosing versus baseline decreased
Study shows reduction in average number of days HSV-2 detected in patients versus baseline
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.91 |
Change
-0.270(5.21%) |
Mkt cap ! $76.12M | |||
| Open | High | Low | Value | Volume |
| $5.15 | $5.15 | $4.88 | $58.96K | 11.74K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 497 | $4.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.95 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| AVR (ASX) Chart |